businessbriefs
10:09in productionCh. 1 · Expropriation, not entrepreneurship/ 10:09 · ceiling 15 min
Companies

Merck & Co.

George Merck · 1891

Merck & Co. did not invent modern pharma — it bought, merged, and outsourced its way into it.

Merck & Co. is a multinational pharmaceutical company founded in 1891 as the American affiliate of the German Merck Group, made independent in 1919 after U.S. government expropriation and resale. Its early growth came from strategic mergers — not organic R&D — and its landmark streptomycin breakthrough relied on external academic research funded by the company. Under George W. Merck’s presidency (1925–1950), it developed synthetic vitamins, sulfas, antibiotics, and hormones, while simultaneously leading the U.S. biological weapons programme. The gap between its self-presentation as a scientific pioneer and its actual mechanics — acquisition, outsourcing, and state-aligned research — is the core of its business story.

CompaniesChemistryThe interwar yearsMedicineChemistry across the network →
Chapters & takeaways4
  1. 1:06
    Expropriation, not entrepreneurship

    Merck & Co. began as a foreign subsidiary — then became independent only after U.S. seizure and a $3.5 million auction buyback.

  2. 2:46
    Growth by acquisition

    Every major therapeutic capability before 1940 came via merger — quinine, vaccines, antitoxins — not internal R&D.

  3. 4:28
    Science on contract

    Streptomycin — its first blockbuster — was discovered in a Rutgers lab funded by Merck, not inside its own walls.

  4. 5:54
    Dual-use science

    Its interwar scientific output coexisted with direct leadership of the U.S. biological weapons programme — same executive, same era.

Worth your time?

Yes. Study the whole thing.

3.5/ 5
What works
  • shows how merger strategy built therapeutic capability
  • reveals the material conditions behind a 'scientific' reputation
What does not
  • establishes a self-sustaining R&D engine before the 1940s
  • proves that its scientific leadership was independent of state infrastructure
Study it if
  • historians of pharmaceutical industry structure
  • students of public–private research funding
Skip it if
  • founders seeking a 'disruption' playbook
  • investors assessing current valuation drivers
The written brief1 min read

What the company or idea is

Merck & Co. is a multinational pharmaceutical company founded in 1891 as the American affiliate of the German Merck Group, made independent in 1919 after U.S. government expropriation and resale.

How it actually makes money

Merck & Co. makes money by developing, manufacturing, and selling pharmaceuticals — including synthetic vitamins, sulfas, antibiotics like streptomycin, and hormones — and vaccines acquired via merger.

What works

Its merger strategy worked: acquiring Powers-Weightman-Rosengarten gave quinine capacity; the Sharp & Dohme–Mulford link brought vaccine technology used in WWI cavalry immunisation and diphtheria antitoxin delivery.

What does not

The company does not establish a continuous, self-contained R&D pipeline before the 1940s. Its major therapeutic breakthroughs relied on external academic partnerships (e.g., Rutgers) and wartime state programmes (e.g., War Research Service), not internal discovery engines.

What to take from it

Merck & Co.’s early growth came from strategic mergers (Powers-Weightman-Rosengarten, Sharp & Dohme), not organic scale — and its scientific reputation rests on funded external research and wartime state collaboration, not proprietary lab dominance.

Is it worth your time

Yes, if you are studying how pharmaceutical firms institutionalised R&D, leveraged government-linked research funding, or navigated wartime state contracts — not as a case of innovation heroism, but of structural alignment with U.S. scientific and military infrastructure.

Same desk · Companies4 of 217
12:57
MeituanWang Xing · 2010Meituan is a Chinese technology company headquartered in Beijing that operates a platform for local services, including on‑demand food delivery, in‑store services, consumer reviews under Dazhong Dianping, hotel and travel bookings, and instant retail. It monetises through fees on its platform, taking a commission on food delivery orders and charging merchants for booking and in‑store services. Meituan’s rapid user growth is driven by its extensive coverage of local services, its integration of food delivery, in‑store services, and hotel bookings creating a one‑stop shop, and its large merchant base of 14.5 million active merchants providing network effects. Meituan faces regulatory scrutiny in China, its 2021 post by Wang Xing triggered a 7.1 % share plunge and anti‑monopoly investigation, and the company has been subject to scrutiny by Beijing Municipal Human Resources and Social Security Bureau. Meituan demonstrates the power of a diversified local‑services platform, its ability to scale across cities and internationally shows the importance of network effects, and its regulatory challenges highlight the need for compliance awareness. Meituan offers a case study in rapid scaling and diversification, but its regulatory risks caution investors.
10:56
ABBCharles Eugene Lancelot Brown · 1988ABB is a post-merger industrial incumbent whose value lies in proven, regulated, physical infrastructure — not software, platforms, or scalability stories.
10:50
AbbVie2012AbbVie is a textbook example of post-innovation pharmaceutical value extraction — built on a single blockbuster, sustained by patent thickets and pricing, checked only by biosimilars and congressional scrutiny.
11:08
Abu Dhabi National Oil Company1971ADNOC is the state-owned oil company of Abu Dhabi, UAE — founded by concession in 1939, ranked 12th globally by production, and expanding output to 5 million barrels per day by 2027. It is the UAE’s largest oil company. Output rose from ~2.5 mbpd in the 1990s to 2.9 mbpd in 2008 and 4.85 mbpd in 2024. It is described as efficient and well managed, but financially opaque. It is one of few oil companies increasing production amid climate pressure.
Up next in Business

Acquisition of Activision Blizzard by Microsoft

· 10:38

This wasn’t about Call of Duty — it was about owning the right to decide which games players pay for, where, and how often.

Play nextBack to Companies
10:38